HD Research HD Research Webinar Series

HD Research Webinars Series

In an effort to increase research communication between HD families/patients and the HD Scientists around the world, HDSA offers the HD Research Webinar Series, a series of monthly webinars on current research topics presented by HD experts from around the globe. The webinars commence at 12:00 PM EST and run for approximately 30-40 minutes, with 20-30 minutes available for a question and answer session through a chat feature of the webinar software. Each session will end by 1:00 PM EST. We chose this time to allow you to participate in this over your lunch hour, making this a virtual luncheon seminar.

Webinars

If your have questions or suggestions for future seminar topics, please send them to researchupdates@hdsa.org

Webinars

TITLE PRESENTERS ORIGINAL AIR DATE

2018 Year in Review 1/16/2019

RNAi-based huntingtin lowering in the central nervous system: a new potential HD therapeutic Julia Alterman 10/18/2018

Update on Huntington's Program and Clinical Trials from Roche/Genentech 9/26/2018

Exercise for the brain and body the benefits of physical activity in Huntingtons 5/25/18

Neural Stem Cells as a Therapeutic Candidate for Huntington's Disease Jack Reidling, PhD 4/25/18

How can sheep help us develop huntingtin lowering therapies? Edith Pfister, MD 3/21/2018

Selective Targeting of Mutant Huntingtin (mHTT) presented by Wave Life Sciences. 2/7/2018

2017 Huntington's Disease Research Year in Review Webinar 1/17/2018

The SIGNAL Phase 2 Trial Clinical Development of VX15 Anti Semaphorin 4D Antibody as a potential treatment for HD 9/17/2017

What's the Deal with Neurofilament: A Blood Test that Predicts Huntington's Disease Progression? Dr. Ed Wild & Lauren Byrne November 15, 2017

Interim Results from the Vaccinex SIGNAL Trial Maurice Zauderer 9/19/17

Potential new drug target identified that could correct protein misfolding in Huntington’s disease Dennis J. Thiele & Rocio Gomez-Pastor, Ph.D Wed, Apr 5, 2017

2016 Year in Review 2/1/17

PRIDE-HD Clinical Trial Results Dr. Andrew McGarry Wednesday, January 11th, 2017

Is HD More Prevalent Than Previously Thought? Chris Kay 9/7/16

The FDA and Patient Engagement – What’s Next for the HD Community Dr. John Whyte 5/12/2016

PPAR delta is decreased in HD and can be targeted therapeutically Al LaSpada, MD, PhD 4/28/2016

LEGATO-HD: A Clinical Study in Subjects with Huntington's Disease to Assess the Efficacy and Safety of Laquinimod Spyros Papapetropoulos, MD, PhD 2/3/16

The role of complement and synaptic loss in driving disease progression in Huntington’s disease Daniel Wilton, PhD 3/16/16

2015: The Year in Review for HD Research George Yohrling, PhD 1/21/16

At Home Monitoring of Sleep/Wake Cycles in Huntington’s Disease Patients Dr. Dawn Loh December 9, 2015

PF-02545920: An Investigational Pfizer Compound for the Treatment of Huntington's Disease Ottavio Vitolo November 19, 2015

Genetic variation in huntingtin promoter as a bidirectional genetic modifier of Huntington’s disease Dr. Kristina Becanovic October 7, 2015

The spread of mutant huntingtin protein from cell to cell and its implications for transplant therapies for Huntington's disease Francesca Cicchetti, PhD April 16, 2015

Suppression of somatic expansion of CAG tract delays onset of disease in mouse model of HD Helen Budworth, PhD September 16, 2015

Histone deacetylase (HDAC) inhibitors: assessing their potential for clinical use. Beth Thomas, PhD March 19, 2015

Stem Cells in HD Research and Therapeutics Jamshid Arjomand, PhD February 27, 2013

Huntingtin ASOs Holly Kordasiewicz, PhD March 19, 2013

Sleep/Circadian Dysfunction in HD Jenny Morton, PhD- University of Cambridge April 24, 2013

Enroll-HD Joe Giuliano, CHDI Foundation May 22, 2013

Kids-HD: Brain Imaging Research Study Peg Nopoulos July 24, 2013

Clinical Trials in Premanifest HD: Review of PREQUEL Results and Prospects for the Future Chris Ross August 22, 2013

PDE10 Imaging in HD Patients Ken Marek September 26, 2013

“FIRST-HD: A clinical Trial to test effectiveness of novel drug for reducing HD chorea” Sam Frank, MD and Claudia Testa, MD, PhD November 21, 2013

Year in Review George Yohrling, Ph.D. January, 22, 2014

Silencing Mutant Huntingtin as a Therapy for HD Neil Aronin, MD (University of Massachusetts Medical School) March 27, 2014

Mind the Gap: Thinking Big to Bridge Drug Development in Huntington’s Disease David Howland, Ph.D. May 22, 2014

Using mouse models to gain therapeutic insights for Huntington's disease William Yang, MD, PhD (UCLA) August 21, 201

Allele-specific silencing of mutant huntingtin gene with ASOs Dr. Amber Southwell (University of British Columbia) September 24, 2014

Stem Cell Approaches for HD Dr. Vicki Wheelock and Dr. Jan Nolta (UC-Davis) October 7, 2014

2014: The Year in Review for HD Research George Yohrling, PhD January 21, 2015

Pride- HD: a dose finding, safety and efficacy study of pridopidine in HD patients Dr. Michael Hayden February 10, 2015

The spread of mutant huntingtin protein from cell to cell and its implications for transplant therapies for Huntington's disease Francesca Cicchetti, PhD April 16, 2015

CLICK HERE TO VIEW THE HDSA CAREGIVER’S CORNER WEBINAR SERIES